Alembic Pharmaceuticals receives USFDA Final Approval for Doxycycline Hyclate Delayed-Release Tablets

Alembic Pharmaceuticals Limited today announced that it has received final approval from the USFDA for its ANDA for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg.

Related Keywords

,Alembic Pharmaceuticals Limited ,Alembic Pharmaceuticals ,Us Food Drug Administration ,Mayne Pharma International Pty ,Pharmaceuticals Limited ,Drug Administration ,Abbreviated New Drug Application ,Doxycycline Hyclate Delayed Release Tablets ,Doryx Tablets ,Mayne Pharma International ,Doxycycline Hyclate Delayedrelease Tablets ,Alembicpharmaceuticals ,Ine901l01018 ,Usfda ,Panda ,Finalapproval ,Doxycyclinehyclate ,Delayedreleasetablets ,